Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Virkninger af Ecopipam eller Placebo hos voksne med stamming (tal frit)

22. september 2026 opdateret af: Emalex Biosciences Inc.

Et multicenter, randomiseret, dobbeltblindt, placebokontrolleret, parallelgruppe, fase 2 eksplorativt studie for at evaluere effektiviteten og sikkerheden af ​​Ecopipam-tabletter hos voksne med begyndende flydende lidelse (stamming)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

At the Baseline visit, eligible subjects will be randomized 1:1 to receive either a target steady-state dose of ecopipam HCl ~2 mg/kg/day or matching placebo for a 12-week Treatment Period consisting of a 4-week Titration Phase followed by an 8-week Maintenance Phase.

Subjects will return to the clinic at 4, 8, and 12 weeks after Randomization and Follow-up visits 7 and 14 days after completing the Treatment Period or Early Discontinuation. Efficacy assessments will be conducted at Weeks 4, 8, and 12 and safety assessments will be conducted at all visits. Subjects will have adverse events and other safety parameters assessed by phone or video conference at Weeks 2, 6 and 10 and 30 days after the last study drug administration. Signs or symptoms of withdrawal, abuse, and dependence will be monitored throughout the study.

At the end of the Treatment Period or Early Discontinuation, subjects will taper study drug by 25 mg/day until off study drug, for up to 1 week.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

68

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Riverside, California, Forenede Stater, 92501
        • UC Riverside
      • Santa Ana, California, Forenede Stater, 92705
        • CI Trials
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32256
        • Clinical Neuroscience Solutions Inc
      • Orlando, Florida, Forenede Stater, 32801
        • Clinical Neuroscience Solutions Inc
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30341
        • Institute For Advanced Medical Research
    • Kansas
      • Prairie Village, Kansas, Forenede Stater, 66208
        • Social Psychiatry Research Institute
    • Michigan
      • East Lansing, Michigan, Forenede Stater, 48824
        • Michigan State University
    • New York
      • Brooklyn, New York, Forenede Stater, 11235
        • Social Psychiatry Research Institute
    • Tennessee
      • Memphis, Tennessee, Forenede Stater, 38119
        • Clinical Neuroscience Solutions Inc

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Able to read and write in English and provide informed consent
  • 18 years or older of age at screening
  • Weighs >= 45 kg (~99 lbs)
  • Satisfies DSM-5 criteria for childhood onset fluency disorder
  • History of stuttering for >=2 years with onset consistent to developmental in nature
  • Must meet an allowed severity of stuttering at screening and baseline, scored by a central rater
  • Completed an adequate course of speech therapy
  • Has a qualifying IOS or Android smartphone
  • Must discontinue all medications used to treat stuttering for at least 14 days prior to screening
  • Sexually active females of child bearing potential must be using effective contraception during and 30 days after participation
  • Sexually active males must use a double barrier method of contraception during and 30 days after participation

Exclusion Criteria:

  • Stuttering is related to a known neurological cause
  • Initiation of new behavioral therapies for stuttering within 10 weeks prior to baseline
  • Unstable medical illness or clinically significant abnormalities on screening tests/exams
  • At a significant risk of committing suicide
  • Are pregnant or lactating
  • Positive urine drug screen
  • Lifetime history of major depressive episode
  • History of seizures
  • Have been previously treated with ecopipam
  • Unstable use of medications prior to screening
  • Use of prohibited medications or need for medications which would have unfavorable interactions with ecopipam
  • Not suitable for study in the opinion of the Principle Investigator

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Ecopipam HCl ~2mg/kg/day

Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks

Oral tablet

Placebo komparator: Matching Placebo

Matching placebo tablets for daily, oral administration for 12 weeks

Oral tablet

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Stuttering Severity Instrument, 4th Edition (SSI-4)
Tidsramme: 12 weeks

The SSI-4 is a reliable and valid norm-referenced stuttering assessment that can be used for both clinical and research purposes. It takes 15-20 minutes to complete. It measures stuttering severity in both children and adults in the 4 areas of speech behavior:1. frequency 2. duration 3. physical concomitants 4. naturalness of the individual's speech.

Frequency is expressed in percent of syllables stuttered and is converted to scale scores of 2-18. Duration is timed to the nearest one tenth of a second and is converted to scale scores of 2-18. The 4 types of physical concomitants are converted to scale scores of 0-56.

12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Global Impression - Severity (CGI-S) Baseline to Week 12
Tidsramme: Baseline, Week 4, Week 8 and 12 weeks

The CGI consists of two reliable and valid 7-item Likert scales used to assess severity and change in clinical symptoms. The severity scale (CGI-S) ranges from 1 (Normal, not ill) to 7 (extremely ill). Pediatric and adult versions of the CGI-TS-S and CGI-TS-I scales are available and will be administered according to the age of the subject at the time of Informed Consent. The efforts of peers, teachers and parents to assist, accommodate, or support the subject should be considered in overall severity in the case of pediatric subjects.

Baseline, Week 4, Week 8 and 12 weeks
Change From Baseline Subjective Screening of Stuttering (SSS)
Tidsramme: From baseline (enrollment) to Week 12.

The Subjective Screening of Stuttering (SSS) research edition is designed to quantify the selected self-reports of people who stutter prior to, during, and following their treatment. The three areas screened by the SSS are perceived stuttering severity (range 3-27), the locus of control subtest (range 6-54), and reported word or situation avoidance (range 6-54). Each of the areas has two or three items rated for three audiences on a 1 to 9, equal appearing scale in which 1 represents "normal" or target level and 9 is the most severe. The total score has a range of 15-135. Higher scores indicate greater severity.

From baseline (enrollment) to Week 12.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Atul R Mahableshwarkar, MD, DFAPA, Emalex Biosciences Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. oktober 2020

Primær færdiggørelse (Faktiske)

7. marts 2022

Studieafslutning (Faktiske)

4. april 2022

Datoer for studieregistrering

Først indsendt

27. juli 2020

Først indsendt, der opfyldte QC-kriterier

27. juli 2020

Først opslået (Faktiske)

30. juli 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. august 2025

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EBS-101-COFD-201

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .